Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment
Authors' conclusion
In this prospective study, when people with T2D on stable GLP-1 RA treatment were switched directly to tirzepatide 5 mg, they experienced improved glycemic outcomes and additional weight reduction with an acceptable risk of adverse gastrointestinal events over 12 weeks.
Study context
- Population
- Adults ≥18 years with T2D, HbA1c ≥6.5% to ≤9.0%, BMI ≥25 kg/m², on stable GLP-1 RA dose (liraglutide, semaglutide or dulaglutide) for ≥3 months; mean age 58.3 years, baseline HbA1c 7.39%, BMI 35.18 kg/m², 55% female
- Exposure
- Direct switch from GLP-1 RA to tirzepatide 5 mg
- Outcome
- HbA1c change from baseline
- Follow-up
- Week 12
Main finding
As reported in the abstract
Mean HbA1c change from baseline
Mean HbA1c change from baseline
−0.43%
Observational data: associations, not effects.
Secondary outcomes
Fasting serum glucose change from baseline · week 12
- Fasting serum glucose change from baseline
- −7.83 mg/dL
- P < .01
Body weight change from baseline · week 12
- Body weight change from baseline
- −2.15 kg
- P < .01
Glycemic outcomes and body weight by baseline GLP-1 RA subgroup
- Glycemic outcomes and body weight improved in all baseline GLP-1 RA subgroups
Safety
- Gastrointestinal events
- 20 (13.2%)
- Discontinued tirzepatide due to adverse events
- 3 (2%)
- Severe hypoglycemic events
- 0
- Deaths
- 0
Original publication
Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →